Olaparib

Aug 16, 2019

With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis

Jan 25, 2019

Global PARP Inhibitors in Oncology Research Report 2018: Background, Mechanism of Action, and Clinical Development of PARP Inhibitors

Sep 06, 2018

Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer

Apr 16, 2018

Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals' EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer

Jan 12, 2018

FDA approves first treatment for breast cancer with a certain inherited genetic mutation

Oct 03, 2017

DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

Aug 22, 2017

Clinical and Regulatory Progress Boosting Biotech Sector